The Blincyto (blinatumomab) Humanitarian Access program was created to provide access to Blincyto for pediatric patients with B-cell precursor Acute Lymphoblastic Leukemia (ALL) living in low- to middle-income countries where Blincyto is not commercially available (and where there are very limited treatment options).

Amgen partners with St. Jude Children’s Research Hospital (a global leader in pediatric cancer care) and Direct Relief (a non-profit organization well known for its logistics capabilities in LMICs) to implement the program. Carefully selected and qualified hospitals receive Blincyto for qualifying patients, together with training and ongoing support to ensure safe administration and patient care. The medical training not only build the skills of the doctors and nurses to safely use Blincyto, but also the capabilities of hospitals in immunotherapy more generally.